Originally Posted by Big Girtha
Anti depressants are notorious for killing libido. In the US they are dispensed by doctors like candy. “Here take this pill, it will make you feel happy. You may have sexual side-effects, but you won’t care. You will still have the same problems that got you depressed in the first place, but you won’t care. Just don’t stop taking it or you may feel suicidal.”Forget the pill. Some good bud will do you better. You’ll feel happy, you will be a horny motherfucker, and you won’t kill yourself if you run out. You will still have the same problems that got you depressed in the first place, but you won’t remember what they were. :cancer:
Awesome post BG. SSRI’s are known for killing libidos across America. What they do exactly is delay and numb orgasm and possibly weaken erections, and rarely cause impotence to be exact. I remember my brief stint with Zoloft and I didn’t get any side effects except delayed orgasm which I sort of enjoyed. My erections were still hard from what I remember, but I was 18 when I took it and in the peak of my cock-hood.
Marijuana is a great escape from reality as opposed to alcohol, but marijuana shouldn’t be used all day everyday; you will get burned out eventually and a quarter ounce a week of fire weed gets expensive. I had a hundred dollar a week weed habit and it adds up to a Lexus payment.
The only anti-depressant on the market that doesn’t effect libido in a negative way is Wellbutrin (bupropion HCL).
I pulled up some info from wikipedia about bupropion the active ingredient in Wellbutrin because a lot of guys on this forum are interested in this med and may be interested in knowing about it more.
I copy-pasted the paragraphs of interest about bupropion. Sexual dysfunction, anxiety, and attention-deficit disorder. The reason why I like bupropion so much is because it never has lost its edge since I started taking it almost 3 years ago. It works just as good as it did since it first became effective. Just like anything in life you have to be productive in life in order for it to help. Bupropion will not benefit negative people with “born to lose” tattoos on their chest’s.
It is an atypical antidepressant and smoking cessation aid. Bupropion is different than most anti-depressants commonly prescribed in that it primarily acts as a dopamine reuptake inhibitor. It also acts as a norepinephrine, as well as α3β4-nicotinic receptor antagonist. Bupropion belongs to the chemical class of aminoketones and is similar in structure to stimulants cathinone and diethylpropion, and to phenethylamines in general.
Sexual dysfunction
Bupropion is one of few antidepressants that does not cause sexual dysfunction. According to a survey of psychiatrists, it is the drug of choice for the treatment of SSRI-induced sexual dysfunction, although this is not an FDA-approved indication. Thirty-six percent of psychiatrists preferred switching patients with SSRI-induced sexual dysfunction to bupropion, and 43 percent favored the augmentation of the current medication with bupropion. There are studies demonstrating the efficacy of both approaches; improvement of the desire and orgasm components of sexual function were the most often noted. For the augmentation approach, the addition of at least 200 mg/day of bupropion to the SSRI regimen may be necessary to achieve an improvement since the addition of 150 mg/day of bupropion did not produce a statistically significant difference from placebo.
Several studies have indicated that bupropion also relieves sexual dysfunction in people who do not have depression. In a mixed-gender double-blind study, 63% of subjects on a 12-week course of bupropion rated their condition as improved or much improved, versus 3% of subjects on placebo. Two studies, one of which was placebo-controlled, demonstrated the efficacy of bupropion for women with hypoactive sexual desire, resulting in significant improvement of arousal, orgasm and overall satisfaction. Bupropion also showed promise as a treatment for sexual dysfunction caused by chemotherapy for breast cancer and for orgasmic dysfunction. As with the treatment of SSRI-induced sexual disorder, a higher dose of bupropion (300 mg) may be necessary: a randomized study employing a lower dose (150 mg) failed to find a significant difference between bupropion, sexual therapy or combined treatment. Bupropion does not adversely affect any measures of sexual functioning in healthy men
Anxiety
Bupropion has shown some success in treating social phobia and anxiety comorbid with depression, but not panic disorder with agoraphobia. Its anxiolytic potential has been compared to that of sertraline and doxepin. However, it can cause agitation in some patients, especially at higher doses, and often increases anxiety, much like methylphenidate. As a psychostimulant, it is inherently an anxiogenic compound and contrary benefits are poorly understood and seemingly paradoxical.
Attention-deficit hyperactivity disorder
Although attention-deficit hyperactivity disorder (ADHD) is not an approved indication, bupropion was found to be effective for adult ADHD. There have been many positive case studies and other uncontrolled clinical studies of bupropion for ADHD in minors. However, in the largest to date double-blind study, which was conducted by GlaxoSmithKline, the results were inconclusive. Aggression and hyperactivity as rated by the children’s teachers were significantly improved in comparison to placebo; in contrast, parents and clinicians could not distinguish between the effects of bupropion and placebo. The 2007 guideline on the ADHD treatment from American Academy of Child and Adolescent Psychiatry notes that the evidence for bupropion is “far weaker” than for the FDA-approved treatments. Its effect may also be “considerably less than of the approved agents… Thus it may be prudent for the clinician to recommend a trial of behavior therapy at this point, before moving to these second-line agents.” Similarly, the 2006 guideline from the Texas Department of State Health Services recommends considering bupropion or a tricyclic antidepressant as a fourth-line treatment after trying two different stimulants and atomoxetine (Strattera).